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Abstract
In December 2011 the United States House of Representatives introduced a new bill, the Research Works Act (H.
R.3699), which if passed could threaten the public’s access to US government funded research. In a digital age
when professional and lay parties alike look more and more to the online environment to keep up to date with
developments in their fields, does this bill serve the best interests of the community? Those in support of the
Research Works Act argue that government open access mandates undermine peer-review and take intellectual
property from publishers without compensation, however journals like Journal of Translational Medicine show that
this is not the case. Journal of Translational Medicine in affiliation with the Society for Immunotherapy of Cancer
demonstrates how private and public organisations can work together for the advancement of science.
Editorial
Journal of Translational Medicine is an open access
journal published by BioMed Central that aims to opti-
mise communication between basic and clinical science.
Now in its 10
th year of publication the journal is suc-
cessful in its aim for fostering communication from
bench to bedside.
A new bill, the Research Works Act [1], has been
introduced in the United States House of Representa-
tives threatening the public’s access to US government
funded research and the foundation on which Journal of
Translational Medicine was built. The bill states:
“No Federal agency may adopt, implement, maintain,
continue, or otherwise engage in any policy, program,
or other activity that:
(1) causes, permits, or authorizes network dissemina-
tion of any private-sector research work without the
prior consent of the publisher of such work; or
(2) requires that any actual or prospective author, or
the employer of such an actual or prospective author,
assent to network dissemination of a private-sector
research work.”
If passed, this bill would force the retraction of the
public access policy of the National Institutes of Health
[2], who mandate that recipients of their grants must
make their published research publically accessible by
depositing full-text versions in open access repositories
(such as PubMed Central), and prevent similar policies
from being introduced by federal agencies in the future.
It is argued [3,4] that research funded by tax-payers
should be made available to the public free of charge so
that the tax-payer does not in effect pay twice for the
research - first for the research to be done and then to
read the results. As much as this may be true, the big-
gest detriment seems to be to developments in science.
Open access to research means the widest possible dis-
semination of information. Limiting access to a (by
comparison) small subset of people with subscriptions
can stunt further developments.
When peer-reviewed information and data is made
freely available online, text and data mining can help
speed up advances by analysing and trending multiple
datasets that would previously have taken years to
achieve. As more information is made available, such
investigations become more accurate and more
meaningful.
Health care providers regularly access online resources
including research to keep up to date with developments
or to assist specific patients [5]. The same research also
showed that health professionals would like greater
access to information, including research. Access to the
latest research is important for health care providers
who may not always be attached to institutions or
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that clinicians and health care providers are aware of
developments help move ideas from bench to bedside
and can allow improved patient care by benefitting from
the experience of others.
A recent commentary article [6] published in Journal
of Translational Medicine discusses outcomes from a
summit called by the Society for Immunotherapy of
Cancer (SITC), which included representatives from
both public and privately funded organizations from
across the globe. They discuss various hurdles that hin-
der the progression of promising cancer immunothera-
pies to clinical application, although these hurdles may
well resonate within other areas of translational
medicine.
One hurdle discussed relates to the exchange of infor-
mation between different groups of people stating: “...it
is becoming less feasible for a single group to have the
detailed knowledge and resources to investigate, analyze,
select and implement the best strategies to move for-
ward in clinical trials for any given indication.”[6] This
highlights the importance and continual need for shar-
ing information and findings in an open way, to ensure
that potential new therapies can continue to move
forwards.
The SITC is affiliated with the “Tumor immunology
and biological cancer therapy” section of Journal of
Translational Medicine.T h e ya r eo n eo fag r o w i n g
number of societies affiliated with or publishing open
access journals in their fields. There are currently
believed to be over 530 societies publishing at least one
open access journal [7], a figure that is growing in accu-
racy thanks to the community editable record [8].
Maybe one of the reasons that open access is an
increasingly popular choice for society journals is that it
fits well with many society missions to encourage the
advancement of knowledge by providing the widest pos-
sible dissemination with no barriers to access. While the
Research Works Act is supported by the Association of
American Publishers(AAP)[9], several of the AAPs 50+
society and publisher members have already distanced
themselves from the AAPs support of the bill, including
the American Association for the Advancement of
Science, publisher of Science[10], and Nature Publishing
Group [11].
Belief in the benefits of open access publishing con-
tinues to grow demonstrated by a reported 47% growth
in open access articles published in 2011 compared to
2010 and 24% growth in the number of journals in the
Directory of Open Access Journals [12]. Over 50 fund-
ing bodies worldwide currently have policies in support
of open access [13] but by no means do these policies
act to exclude publishers from continuing to publish
articles compiled based on research funded by
government bodies or grants. Publishers, regardless of
the model by which they operate (subscription or open
access covered by author charges), do need to cover the
costs associated with the services they provide. Publish-
ers who are traditionally recompensed for their services
via subscription fees can (and do) offer open access
options, allowing research to be deposited in public
repositories such as PubMed Central after a certain per-
iod of time.
While author choice is fundamental in the publication
process, given the importance of wide access to all
research, whether public and privately funded, should
we stop funders from requiring the results of their fund-
ing be as visible and transparent as possible?
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